Filing Details

Accession Number:
0000950123-20-006736
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-06 21:00:43
Reporting Period:
2020-07-01
Accepted Time:
2020-07-06 21:00:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA Pharmaceutical Preparations (2834) 205993609
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1598480 B James Weissman C/O Dicerna Pharmaceuticals, Inc.
33 Hayden Avenue
Lexington MA 02421
Chief Operating Officer & Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-01 4,360 $2.97 26,220 No 4 M Direct
Common Stock Disposition 2020-07-01 3,053 $26.39 23,167 No 4 S Direct
Common Stock Disposition 2020-07-01 1,307 $26.87 21,860 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-07-01 4,360 $0.00 4,360 $2.97
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,980 2027-01-03 No 4 M Direct
Footnotes
  1. The Reporting Person sold an aggregate of 4,360 shares of common stock on July 1, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.57% of 761,598 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2019.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.705, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.77 to $26.94, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
  5. The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.